News Headlines

  1. Samsung Bioepis And Organon Broaden Biosimilar Access In Australia Through Expanded Commercialisation Agreement 7/16/2026

    Samsung Bioepis Co., Ltd. and Organon, a global healthcare company with deep expertise in biosimilars, have announced the expansion of their Development and Commercialisation Agreement, to commercialise a new biosimilar in Australia by Organon ANZ.

  2. BriaCell Arranges Scalable Manufacturing With FUJIFILM Biotechnologies For Bria-IMT™ 7/15/2026

    BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces a manufacturing arrangement with FUJIFILM Biotechnologies California, a leading contract development and manufacturing organization (CDMO) specializing in cell therapies, to support the ongoing pivotal Phase 3 clinical development and potential future commercial supply of  BriaCell’s lead clinical candidate, Bria-IMT, an off-the-shelf allogenic cell therapy.

  3. Kindeva Appoints Brok Weichbrodt As Chief Transformation Officer To Accelerate Growth Strategy And Commercial Excellence 7/14/2026
  4. Adneuris Therapeutics Grants Exclusive License To Zhejiang Conba Pharmaceutical To Advance Cebranopadol In Greater China 7/14/2026

    Adneuris Therapeutics, a subsidiary of Tris Pharma advancing a new kind of pain medicine, today announced that it has entered into an exclusive license agreement with Zhejiang Conba Pharmaceutical Co., Ltd. (“Conba”) (SSE: 600572).

  5. AstraZeneca Enters Exclusive Global License Agreement For Novel Oral EGFR Inhibitor Zegfrovy For Lung Cancer With Dizal Pharmaceutical 7/14/2026

    AstraZeneca has entered into an exclusive license agreement with Dizal Pharmaceutical Co., Ltd for Zegfrovy (sunvozertinib), a novel oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer. AstraZeneca will acquire worldwide rights to develop and commercialise Zegfrovy.

  6. Evonik Partners With Evitria To Accelerate Early Biologics Development 7/14/2026

    Evonik has partnered with global antibody expression specialist evitria to offer a ready-to-use transient protein expression kit based on CHO cells for biopharmaceutical research and development.

  7. Hansoh Pharma Announces License Collaboration And Strategic Investment With Avere For Oral IL 23 Asset HS 20118 7/14/2026

    Hansoh Pharmaceutical Group Co., Ltd. announced that it has entered into an exclusive license agreement and strategic investment with Avere Therapeutics, Inc. (Avere), an investee company of Hansoh Pharma focused on advancing oral therapies for IL-23 driven inflammatory diseases.

  8. Dizal Announces Global Exclusive License Agreement With AstraZeneca For Zegfrovy 7/14/2026

    Today, Dizal announced that it has entered into a global exclusive license agreement with AstraZeneca for Zegfrovy (sunvozertinib), a novel oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer. AstraZeneca will acquire worldwide rights to develop and commercialise Zegfrovy.

  9. Insilico Medicine And Bora Pharmaceuticals Announce Strategic Alliance For AI-Driven Drug Discovery And Development 7/14/2026

    Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced a multi-target strategic alliance with Bora Pharmaceuticals Co., Ltd. ("Bora"; TWSE: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing.

  10. Innovent Biologics And Spero Therapeutics Announce Exclusive License For IBI355 (SP001), A Phase 2-Ready Third-Generation Anti-CD40L Antibody 7/14/2026